Supernus Pharmaceuticals shares are trading lower after the company announced the FDA has issued a Complete Response Letter in response to the company's New Drug Application for SPN-830.
Portfolio Pulse from Benzinga Newsdesk
Supernus Pharmaceuticals' stock is trading lower following the FDA's issuance of a Complete Response Letter regarding the company's New Drug Application for SPN-830.
April 08, 2024 | 12:20 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Supernus Pharmaceuticals' shares are trading lower due to the FDA's Complete Response Letter for SPN-830.
The FDA's Complete Response Letter is a significant regulatory setback for Supernus Pharmaceuticals, directly impacting investor confidence and the perceived future revenue potential of SPN-830. This news is likely to cause a short-term decrease in the company's stock price due to the negative implications for the drug's approval process and potential market entry delays.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100